CL2-SN38 manufacturers
- CL2-SN-38
-
- $829.00 / 50mg
-
2024-10-24
- CAS:1036969-20-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | CL2-SN38 Basic information |
| Product Name: | CL2-SN38 | | Synonyms: | CL2-SN38;CS-2807;L-Lysinamide, N-[32-[4-[[[[4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-1,5-dioxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azadotriacont-1-yl]-L-phenylalanyl-N-[4-[[[[[(4S)-4,11-diethyl-3,4,12,14-tetrahydro-9-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,...;CL2-SN-38(DCA) | | CAS: | 1036969-20-6 | | MF: | C82H106N12O23 | | MW: | 1627.81 | | EINECS: | | | Product Categories: | ADC LINKER | | Mol File: | 1036969-20-6.mol |  |
| | CL2-SN38 Chemical Properties |
| density | 1.38±0.1 g/cm3(Predicted) | | pka | 9.12±0.40(Predicted) | | form | Solid | | color | Light yellow to green yellow |
| | CL2-SN38 Usage And Synthesis |
| Uses | CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer[1]. | | IC 50 | Camptothecins | | References | [1] Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. DOI:10.1158/1078-0432.CCR-10-2939 |
| | CL2-SN38 Preparation Products And Raw materials |
|